Etoricoxib

Etoricoxib
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	AU: C; Not recommended;
Routes of; administration	By mouth
ATC code	M01AH05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); UK: POM (Prescription only);
Pharmacokinetic data
Bioavailability	100%
Protein binding	92%
Metabolism	Liver, CYP extensively involved (mainly CYP3A4)
Elimination half-life	22 hours
Excretion	Kidney (70%) and fecal (20%)
Identifiers
	IUPAC name 5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine;
CAS Number	202409-33-4 ;
PubChem CID	123619;
IUPHAR/BPS	2896;
DrugBank	DB01628 ;
ChemSpider	110209 ;
UNII	WRX4NFY03R;
KEGG	D03710 ;
ChEBI	CHEBI:6339 ;
ChEMBL	ChEMBL416146 ;
CompTox Dashboard (EPA)	DTXSID3046457 ;
ECHA InfoCard	100.207.709
Chemical and physical data
Formula	C18H15ClN2O2S
Molar mass	358.84 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(c3ccc(c2cc(Cl)cnc2c1cnc(cc1)C)cc3)C;
	InChI InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3 ; Key:MNJVRJDLRVPLFE-UHFFFAOYSA-N ;
	(verify)

Etoricoxib, sold under brand names including Arcoxia, Exinef and Nucoxia is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.^[3]

It was patented in 1996 and approved for medical use in 2002.^[4]

^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
^ "Merck & Co., Inc. (Jobs) Receives Non Approvable Letter from FDA for Arcoxia (etoricoxib)". BioSpace. Retrieved 15 October 2023.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 522. ISBN 978-3-527-60749-5.

[1] "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

[2] Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

[3] "Merck & Co., Inc. (Jobs) Receives Non Approvable Letter from FDA for Arcoxia (etoricoxib)". BioSpace. Retrieved 15 October 2023.

[Fis2006-4] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 522. ISBN 978-3-527-60749-5.

[1]

[2]

[3]

[4]